Experience on Therapy of Adrenoleukodystrophy and Adrenomyeloneuropathy
- 16 December 1991
- journal article
- clinical trial
- Published by S. Karger AG in Developmental Neuroscience
- Vol. 13 (4-5) , 274-279
- https://doi.org/10.1159/000112173
Abstract
We report the biochemical and clinical results obtained during a dietary erucic acid (C22:1) therapy in 20 patients affected by X-linked adrenoleukodystrophy (ALD). Six patients were very severely affected, 9 had milder neurological symptoms and 5 were presymptomatic. Mean basal levels of plasma C26:0 were 1.41 ± 0.48 µg/ml in ALD patients (control values: 0.33 ± 0.12). In all patients C26:0 decreased to virtually normal values. In spite of good biochemical response and absence of consistent side effects of therapy, no encouraging data were observed during the clinical follow-up. The presymptomatic subjects were still free of symptoms after more than 1 year of therapy. The symptomatic patients, however, worsened or did not show any improvement.Keywords
This publication has 0 references indexed in Scilit: